- The FDA has approved Abbott Laboratories (NYSE:ABT) new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy.
- The next generation of Abbott’s proprietary BurstDR stimulation, FlexBurst360 therapy, offers pain coverage across up to six areas of the trunk and/or limbs and enables programming that can be adjusted as a person’s therapeutic needs evolve.
- The Proclaim Plus SCS system is recharge-free with a battery lasting up to 10 years. It can be used with Abbott’s NeuroSphere Virtual Clinic connected care technology, which allows a person to communicate with a physician through secure in-app video chat and remotely receive stimulation settings in real-time.
- SCS therapy, also known as neurostimulation, is an implanted device that sends mild electrical pulses to the nerves along the spinal cord to relieve chronic pain.
- BurstDR therapy is Abbott’s exclusive stimulation technology that delivers pulses – or bursts – of mild electrical energy to alter pain signals as they travel from the spinal cord to the brain.
- Price Action: ABT shares are down 1.25% at $106.09 on the last check Tuesday.
Justice Department Accuses Boeing Of 2021 Settlement Breach
The U.S. Justice Department claims Boeing (NYSE: BA) violated a 2021 settlement tied to fatal 737 MAX crashes. The settlement allowed Boeing to avoid prosecution by enhancing compliance. Recent findings suggest Boeing failed these commitments, risking criminal charges. Boeing had admitted misleading regulators, leading to crashes. A new investigation into a 737 MAX incident and 787 Dreamliner inspection lapses raises further safety concerns.
